Yohan Gerber-Ferder
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Postdoctoral fellowship
Open Date: 2023-01-01
Close Date: 2026-01-01
Grant: Close
Extra thesis year
Open Date: 2021-10-01
Close Date: 2022-10-01
Grant: Close
Thesis
Open Date: 2018-10-01
Close Date: 2021-10-01
Articles (5)
Year:
2026
Year:
2025
T cells that recognize tumor antigens are crucial for mounting antitumor immune responses. Induction of antitumor T cells in immunogenic tumors depends on STING, the intracellular innate immune receptor for cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) and related cyclic dinucleotides (CDNs). However, the optimal way to leverage STING activation in nonimmunogenic tumors is still unclear. Here, we show that cGAMP delivery by intratumoral injection of virus-like particles (cGAMP-VLP) led to differentiation of circulating tumor-specific T cells, decreased tumor regulatory T cells (T regs ), and antitumoral responses that synergized with PD1 blockade. By contrast, intratumoral injection of the synthetic CDN ADU-S100 led to tumor necrosis and systemic T cell activation but simultaneously depleted immune cells from injected tumors and induced minimal priming of circulating tumor-specific T cells. The antitumor effects of cGAMP-VLP required type 1 conventional dendritic cells (cDC1), whereas ADU-S100 eliminated cDC1 from injected tumors. cGAMP-VLP preferentially targeted STING in dendritic cells at a 1000-fold smaller dose than ADU-S100. Subcutaneous administration of cGAMP-VLP showed synergy when combined with PD1 blockade or a tumor T reg -depleting antibody to elicit systemic tumor-specific T cells and antitumor activity, leading to complete and durable tumor eradication in the case of tumor T reg depletion. These findings show that cell targeting of STING stimulation shapes the antitumor T cell response and identify a therapeutic strategy to enhance T cell–targeted immunotherapy.
Year:
2023
Year:
2023
Year:
2023
Collaborators (13)
Judith C Sluimer
Maastricht University Medical Centre
Susanna Bodoy
Head of the Department
Universitat de Vic - Universitat Central de Catalunya
Julie Helft
Group leader
Institut Cochin
Erik Biessen
University of Maastricht
Nicolas Manel
PSL Research University
Laurent Yvan-Charvet
2021 to present | Director of research DR1
INSERM
Bernard Malissen
Researcher / CNRS Investigator (Directeur de Recherche de Classe Exceptionnelle)
CNRS
Marc Dalod
Centre d'Immunologie Marseille-Luminy
FREDERIC FIORE
Head of Genetic Engineering Department, PhD
INSERM Délégation régionale Provence Alpes Cote d'Azur et Corse
Pierre Guermonprez
Institut Pasteur
Sylvain BAULANDE
Head
Institut Curie
Sébastien Dussaud
Sorbonne Université Campus Pierre et Marie Curie
Caroline Hoffmann
-
Make your next move.
Prepare your application
Review drafts before you send them.